Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

nteracting Epidemics in Amazonian Brazil: Prior Dengue Infection Associated With Increased Coronavirus Disease 2019 (COVID-19) Risk in a Population-Based Cohort Stud

Full text
Show less -
Nicolete, Vanessa C. [1] ; Rodrigues, Priscila T. [1] ; Johansen, Igor C. [1] ; Corder, Rodrigo M. [1] ; Tonini, Juliana [1] ; Cardoso, Marly A. [2] ; de Jesus, Jaqueline G. [3, 4] ; Claro, Ingra M. [3, 4] ; Faria, Nuno R. [5, 6, 3, 4] ; Sabino, Ester C. [3, 4] ; Castro, Marcia C. [7] ; Ferreira, Marcelo U. [1]
Total Authors: 12
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo - Brazil
[2] Univ Sao Paulo, Sch Publ Hlth, Dept Nutr, Sao Paulo - Brazil
[3] Univ Sao Paulo, Med Sch, Inst Trop Med, Sao Paulo - Brazil
[4] Univ Sao Paulo, Med Sch, Dept Infect & Parasit Dis, Sao Paulo - Brazil
[5] Univ Oxford, Dept Zool, Oxford - England
[6] Imperial Coll London, Dept Infect Dis Epidemiol, London - England
[7] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA - USA
Total Affiliations: 7
Document type: Journal article
Source: Clinical Infectious Diseases; v. 73, n. 11, p. 2045-2054, DEC 6 2021.
Web of Science Citations: 0

Background Immunity after dengue virus (DENV) infection has been suggested to cross-protect from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mortality. Methods We tested whether serologically proven prior DENV infection diagnosed in September-October 2019, before the coronavirus disease 2019 (COVID-19) pandemic, reduced the risk of SARS-CoV-2 infection and clinically apparent COVID-19 over the next 13 months in a population-based cohort in Amazonian Brazil. Mixed-effects multiple logistic regression analysis was used to identify predictors of infection and disease, adjusting for potential individual and household-level confounders. Virus genomes from 14 local SARS-CoV-2 isolates were obtained using whole-genome sequencing. Results Anti-DENV immunoglobulin G (IgG) was found in 37.0% of 1285 cohort participants (95% confidence interval {[}CI]: 34.3% to 39.7%) in 2019, with 10.4 (95% CI: 6.7-15.5) seroconversion events per 100 person-years during the follow-up. In 2020, 35.2% of the participants (95% CI: 32.6% to 37.8%) had anti-SARS-CoV-2 IgG and 57.1% of the 448 SARS-CoV-2 seropositives (95% CI: 52.4% to 61.8%) reported clinical manifestations at the time of infection. Participants aged >60 years were twice more likely to have symptomatic COVID-19 than children under 5 years. Locally circulating SARS-CoV-2 isolates were assigned to the B.1.1.33 lineage. Contrary to the cross-protection hypothesis, prior DENV infection was associated with twice the risk of clinically apparent COVID-19 upon SARS-CoV-2 infection, with P values between .025 and .039 after adjustment for identified confounders. Conclusions Higher risk of clinically apparent COVID-19 among individuals with prior dengue has important public health implications for communities sequentially exposed to DENV and SARS-CoV-2 epidemics. (AU)

FAPESP's process: 16/18740-9 - Scientific bases for residual malaria elimination in the Brazilian Amazon
Grantee:Marcelo Urbano Ferreira
Support type: Research Projects - Thematic Grants
FAPESP's process: 18/14389-0 - Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE)
Grantee:Ester Cerdeira Sabino
Support type: Research Projects - Thematic Grants
FAPESP's process: 20/04505-3 - Tracking the community-wide spread of SARS-CoV-2: outbreak size, transmission dynamics, clinical outcomes of infection, and duration of naturally acquired antibody responses in an Amazonian town
Grantee:Marcelo Urbano Ferreira
Support type: Regular Research Grants